LLY · News · 20260914N
Regulatory Risk - Retatrutide Black Market
ELI LILLY & Co · 2026-09-14 · Importance 31 · Surprise 42 · In source text
Third-party reporting says bootleg versions of an experimental Eli Lilly drug are circulating in the U.S. Ohio regulators are seeking to stop the supply of the unapproved product. The development creates regulatory, reputational, and potential future commercialization risks for Lilly’s obesity pipeline, although the report does not quantify financial exposure.
Key facts
- As bootleg versions of an experimental drug from Eli Lilly flood the market, regulators are trying to curb supply. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | contingent | — | As bootleg versions of an experimental drug from Eli Lilly flood the market, regulators are trying to curb supply. |